Idorsia Ltd is a Swiss biopharmaceutical company headquartered in Allschwil near Basel, specializing in the discovery, development, and commercialization of innovative small-molecule medicines for unm... Idorsia Ltd is a Swiss biopharmaceutical company headquartered in Allschwil near Basel, specializing in the discovery, development, and commercialization of innovative small-molecule medicines for unmet medical needs. Its purpose is to transform therapeutic options in areas such as central nervous system disorders, cardiovascular conditions, immunology, and rare diseases like Fabry disease. Notable products include QUVIVIQ (daridorexant), a dual orexin receptor antagonist commercially available in the US, Europe, and other regions for treating insomnia by addressing both nighttime and daytime symptoms. JERAYGO (aprocitentan), a dual endothelin receptor antagonist for resistant hypertension, has received approvals in the EU, UK, Switzerland, and Canada. The pipeline features advanced assets like lucerastat for Fabry disease, advancing toward potential registration by 2029, and Phase 3 programs including selatogrel for acute myocardial infarction outlicensed to Viatris. Idorsia operates as a biotech hub in Europe with approximately 938 employees, focusing on high-impact therapies through strategic partnerships and a robust drug discovery engine. In the financial markets, it represents a small-growth player in the biotechnology sector, emphasizing innovation amid evolving clinical milestones.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Idorsia is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Idorsia is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Idorsia's data?

Start your 30-day free trial to request a data review for Idorsia.

Start Free Trial

Legal Center Contact Us